[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":40,"_57":40,"_58":59,"_60":40,"_61":62},"id","a0frgwcpm1aki5rin2o7diwl7","revision",2,"title","Nurix Therapeutics, Inc. 发布 2026 财季第二季度财报","originalTitle","Nurix Therapeutics, Inc. (0001549595) (Filer)","summary","Nurix Therapeutics, Inc. 公布 2026 财季第二季度财务数据。财报显示公司营收、净利润等关键指标未明确披露。该财报为 2026 年 10 月 12 日发布的 press release 内容。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":40,"_93":94,"_95":96},"links",{"_84":85,"_76":86},"publishedAt","2026-10-13T10:19:25.000Z","discoveredAt","2026-10-13T10:37:43.990Z","timelineAt","category","ai-products","tags",[82,83],"stockSymbols",[81],"score",30,"selected",true,"channel","news","story",{"_71":72,"_15":73},"x","readingMode","full","author","language","body",{"_62":75,"_76":-5,"_77":78,"_79":80},"outline",[],"relatedStories",[74],"indexable","markdownAvailable","group",{"_63":64,"_43":65,"_66":67,"_68":69,"_70":69},"hasTranslation","bodyLanguage","zh","factId","fQ80dyBETcOg",{"_71":72,"_15":73},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","1ca7eb00-ce92-4924-803e-2fa1440a8afe","Nurix Therapeutics 2026 财季第二季度财报发布",{"_71":72,"_15":73},"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________________

FORM 8-K

___________________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): October 12, 2026

___________________________________________

NURIX THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________________________


Delaware	001-39398	27-0838048
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

1600 Sierra Point Parkway Brisbane, California		94005
(Address of Principal Executive Offices)		(Zip Code)

(415) 660-5320

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

___________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	NRIX	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On October 12, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2026. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

项目 9.01 财务报表和附录。

(d)附录


附录编号		附录标题或描述

99.1		2026年10月12日的新闻稿

104		封面页面交互式数据文件（嵌入在Inline XBRL文档中）

签名

根据《1934年证券交易法》（修订版）的要求，注册人已 duly 促使本报告由在此 duly 授权的人员代表其签署。


	NURIX THERAPEUTICS, INC.

日期：2026年10 13日	由：	/s/ Arthur T. Sands
		Arthur T. Sands, M.D., Ph.D.
		总裁兼首席执行官

","original","zhKind","translation","complete",false,"NRIX","政策与监管","财报","aihot","/items/a0frgwcpm1aki5rin2o7diwl7","https://www.sec.gov/Archives/edgar/data/1549595/000154959526000048/0001549595-26-000048-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792108800&sig=e4adf00b596060d2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792108800&sig=208b33ec2756b0ea 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792108800&sig=786fcd6a5ff8379c 96w","changelogVersion","2026-10-01T08:00"]